New trial
Feasibility of 5-ALA for Fluorescence-Guided Surgery in Pediatric Brain Tumors
- Trial ID
- NCT06907485 on ClinicalTrials.gov
- Cancer type
- Glioma / Glioblastoma
- Location
- 2 Locations (Pittsburgh, Chicago)
- Published in
- New in Oncology - May 29, 2025
This University of Pittsburgh study is assessing 5-ALA—a small molecule that induces tumor fluorescence—for its feasibility in improving tumor visualization during resection in pediatric patients (ages 2 to 18) with brain tumors.
More in brain and CNS tumors
-
Trial result · Oct 15, 2026 · NCT04365374
Cesium-131 collagen “GammaTile” brachytherapy cuts surgical-bed recurrence vs post-op SRT in resected brain mets -
Trial result · Oct 15, 2026 · NCT03946527
Lanreotide (somatostatin analog) shows disease stabilization in advanced PPGL in a Phase 2 preprint -
New trial · Oct 15, 2026 · NCT07831772
REMIND feasibility study tests a single maintenance IMRT fraction after temozolomide-based treatment in glioblastoma -
New trial · Oct 15, 2026 · NCT07664176
Phase 1 nivolumab plus focused ultrasound and microbubbles tests blood-brain barrier opening in recurrent pediatric brain tumors -
New trial · Oct 15, 2026 · NCT07831369
Phase 2 VISTA combines valproic acid, irinotecan, and simvastatin for recurrent malignant glioma